Submissions for variant NM_058195.4(CDKN2A):c.-25G>T

gnomAD frequency: 0.00001  dbSNP: rs1064795989

Total submissions: 2

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
GeneDx	RCV000479947	SCV000572334	uncertain significance	not provided	2016-11-25	criteria provided, single submitter	clinical testing	This variant is denoted CDKN2A c.-25G>T, and consists of a G>T nucleotide substitution 25 bases upstream of the translation initiation site. The surrounding sequence, with the base that is substituted in brackets, is CCGA[G/T]CTCG. The CDKN2A gene encodes the p16 protein, and using an alternate reading frame, the p14ARF protein as well. This variant occurs just upstream of the start codon for p14ARF and there have not, to our knowledge, been any published regulatory variants in the p14-ARF isoform. Although this variant does not appear to affect the start codon or the Kozak translational consensus sequence of p14-ARF, there are published variants in p16,including c.-34G>T, that are considered to be pathogenic and predispose to melanoma (Liu 1999, Bisio 2010). This variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Based on currently available information, it is unclear whether CDKN2A c.-25G>T is a pathogenic variant or a benign variant. We consider it to be a variant of uncertain significance.
Ambry Genetics	RCV004017642	SCV004848958	uncertain significance	Hereditary cancer-predisposing syndrome	2017-02-13	criteria provided, single submitter	clinical testing	The c.-25G>T alteration is located in the 5' untranslated region (5'UTR) of the CDKN2A gene. This alteration consists of a G to T substitution nucleotides upstream from the first translated codon. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.